Mizuho Medy Co 4595.T · JPY

Its shares trade on Tokyo Stock Exchange under the ticker 4595.T. It has been listed since 17 December 2015. In the fiscal year to 31 December 2025, it reported revenue of ¥11.26bn and net income of ¥3.42bn. At that date it held total assets of ¥22.38bn and shareholders' equity of ¥18.68bn.

Mizuho Medy Co., Ltd. engages in the research, development, manufacture and distribution of in-vitro diagnostic products. The company is headquartered in Tosu-Shi, Saga-Ken. The company went IPO on 2015-12-17. The firm mainly provides in-vitro diagnostic pharmaceuticals, including immune serum test drugs, biochemical test drugs, urine and feces test drugs, microbial test drugs, blood test drugs, pathological test drugs and others, in hospital and medical practitioner fields. In addition, the Company also provides over-the-counter (OTC) drugs to pharmacies and drug stores, and sells fruit tree virus test drugs to which they apply the technology of immune serology test to agricultural test centers.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Fuminari KarakawaChairman of the Board, President, Representative Director, since 1977
• Mr. Toshio KambaraChief Director of Sales, Director of Overseas Business, Director, since 2015
• Mr. Kazuhiro IchimaruDirector of Intellectual Property, Director, since 2010
• Mr. Kenji NaraharaDirector of Development, Director, since 2008
• Mr. Nobuhiro UtoDirector, since 2016
• Mr. Shinichi AkiyamaIndependent Director
• Mr. Katsumi SasakiIndependent Director

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.